Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.71 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.56 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.53 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.53 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.50 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.49 |
| ▸ | IDO1 | P14902 | 1/20 | 0.48 |
| ▸ | AHR | P35869 | 1/20 | 0.47 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL28679046 | 0.98 | LOXL2 (0.69) | LOXL2HRH3MTNR1AMTNR1BAOC3 | |
| Iodide SCHEMBL28690475 | 0.98 | LOXL2 (0.69) | LOXL2HRH3MTNR1AMTNR1BAOC3 | |
| Hydrochloric Acid SCHEMBL28686778 | 0.98 | LOXL2 (0.69) | LOXL2HRH3MTNR1AMTNR1BAOC3 | |
| SCHEMBL1713962 | 0.89 | LOXL2 (0.67) | LOXL2HRH3MTNR1AMTNR1BAOC3 | |
| Indole SCHEMBL6823823 | 0.88 | LOXL2 (0.57) | LOXL2HRH3MTNR1AMTNR1BAOC3 | |
| SCHEMBL7169246 | 0.87 | LOXL2 (0.69) | LOXL2HRH3MTNR1AMTNR1BAOC3 | |
| SCHEMBL31059889 | 0.87 | LOXL2 (0.69) | LOXL2HRH3MTNR1AMTNR1BAOC3 | |
| SCHEMBL30254704 | 0.87 | LOXL2 (0.59) | LOXL2HRH3MTNR1AMTNR1BAOC3 | |
| SCHEMBL8376332 | 0.87 | LOXL2 (0.65) | LOXL2HRH3MTNR1AMTNR1BAOC3 | |
| Hydrochloric Acid SCHEMBL27539522 | 0.87 | LOXL2 (0.65) | LOXL2HRH3MTNR1AMTNR1BAOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 460 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118984868-A | Genetically modified organisms for the production of psychotropic alkaloids | 恩派瑞安神经科学公司 | 2024-11-19 | — | — | CN | claimed |
| US-20230416794-A1 | Engineered Microorganisms for Producing Substituted Tryptamines | ALGAE C INC (CA) | 2023-12-28 | — | — | US | claimed |
| EP-4244333-A1 | ENGINEERED MICROORGANISMS FOR PRODUCING SUBSTITUTED TRYPTAMINES | Algae-C Inc. (CA) | 2023-09-20 | — | — | EP | claimed |
| CN-114748681-B | Injectable self-healing hydrogel dressing and preparation method and application thereof | 四川大学 | 2023-03-10 | — | — | CN | claimed |
| CN-114213395-B | Pyrimidone acyl piperazine compound and preparation method and application thereof | 山东大学 | 2022-10-25 | — | — | CN | claimed |
| CN-114748681-A | Injectable self-healing hydrogel dressing and preparation method and application thereof | 四川大学 | 2022-07-15 | — | — | CN | claimed |
| WO-2022099424-A1 | ENGINEERED MICROORGANISMS FOR PRODUCING SUBSTITUTED TRYPTAMINES | ALGAE-C INC. (CA) | 2022-05-19 | — | — | WO | claimed |
| EP-3989992-A2 | THERAPEUTIC COMPOSITIONS AND METHODS OF USING SEROTONIN MODULATING MICROBIOME-BASED INTERVENTIONS TO TREAT SEROTONIN-RELATED DISEASES OR DISORDERS | Holobiome, Inc. (US) | 2022-05-04 | — | — | EP | claimed |
| CN-114213395-A | Pyrimidone acyl piperazine compound and preparation method and application thereof | 山东大学 | 2022-03-22 | — | — | CN | claimed |
| CN-110643032-B | Eight-arm polyethylene glycol, preparation method, functionalized derivative and modified biologically-relevant substance | 厦门赛诺邦格生物科技股份有限公司 | 2022-01-28 | — | — | CN | claimed |
| EP-2066700-B1 | DEXTRAN FUNCTIONALIZED WITH HYDROPHOBIC AMINO ACIDS | ADOCIA (FR) | 2015-11-11 | — | — | EP | claimed |
| WO-2014089121-A2 | RETROGRADE DELIVERY OF CELLS AND NUCLEIC ACIDS FOR TREATMENT OF CARDIOVASCULAR DISEASES | ICHIM THOMAS (US) | 2014-06-12 | — | — | WO | claimed |
| US-8546356-B2 | Administration form of osteogenic protein complexes | ADOCIA (FR) | 2013-10-01 | — | — | US | claimed |
| US-8497253-B2 | — | — | 2013-07-30 | — | — | US | claimed |
| US-8247556-B2 | Method for preparing 6-substituted-7-aza-indoles | AMGEN INC. (US) | 2012-08-21 | — | — | US | claimed |
| US-20100167984-A1 | Complex between human insulin and an amphiphilic polymer and use of this complex in the preparation of a fast-acting human insulin formulation | ADOCIA (FR) | 2010-07-01 | — | — | US | claimed |
| US-20100166867-A1 | Novel administration form of osteogenic protein complexes | ADOCIA (FR) | 2010-07-01 | — | — | US | claimed |
| US-20100137456-A1 | Polysaccharides functionalized by tryptophan derivatives | ADOCIA (FR) | 2010-06-03 | — | — | US | claimed |
| CN-101631804-A | Dextran functionalized with hydrophobic amino acids | ADOCIA | 2010-01-20 | — | — | CN | claimed |
| WO-2000070027-A1 | MATERIALS AND METHODS FOR ENZYMATIC N-ACETYLATION OF ARYLALKYLAMINES | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTHA ND HUMAN SERVICES (US) | 2000-11-23 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100166867-A1 | Novel administration form of osteogenic protein complexes | BMP2, SOST, SDF4 | LOXL2 3421/4885HRH3 4622/4885MTNR1A 3755/4885 |
| US-20100167984-A1 | Complex between human insulin and an amphiphilic polymer and use of this complex in the preparation of a fast-acting human insulin formulation | IAPP, IRS1, GPR119 | LOXL2 4777/4885HRH3 2196/4885MTNR1A 315/4885 |
| US-20100137456-A1 | Polysaccharides functionalized by tryptophan derivatives | TPH1, TPH2, IDO1 | LOXL2 3594/4885HRH3 347/4885MTNR1A 194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.